COVID-19 Resources and Services from WCG:
COVID-19 Webinar Series
Join the next COVID-19 Webinar
Join thousands of your peers in WCG’s online panels, where clinical trial and public health experts provide the latest insights on COVID-19 and discuss the biggest questions and topics you submit.
COVID-19 Clinical Trial Tracker
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
COVID-19 Trial Insights from the WCG Knowledge Base™
About WCG Trial Insights
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
WCG COVID-19 Advisory Services
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
Insights from January 8, 2021
More Than 70 Planned COVID-19 Trials in the U.S. Yet To Initiate
There are 71 industry-sponsored clinical trials for COVID-19 currently being planned in the U.S., many with lapsed start dates. Of the total, 38 are focused on mitigating clinical impact, 22 are designed to test antiviral effect, 9 are vaccine trials, and 2 are to address post-COVID-19 symptoms.
Recent Insights from WCG
The map below displays WCG locations. The same locations are listed below the map.
Watch Recent COVID-19 Webinars
Recent news on COVID-19 and clinical trials
News provided by WCG FDAnews and WCG CenterWatch
Synairgen Begins Dosing in Phase 3 Trial of Inhaled COVID-19 Treatment
UK drugmaker Synairgen has dosed the first patient in a global phase 3 trial evaluating an inhaled formulation of interferon beta-1a, SNG001, for treating hospitalized COVID-19 patients who require supplemental oxygen.
Oxford Immunotec Pitches in on Valneva’s Early-Stage COVID Vaccine Trial
Oxford Immunotec is teaming up with Valneva to help the French biotech with a phase 1/2 UK trial of its inactivated COVID-19 vaccine candidate, VLA2001.
FDA Offers Advice on Potency Assays for Therapeutic Protein COVID-19 Treatments
The FDA has issued straight-to-final guidance that provides sponsors of monoclonal antibody and other therapeutic protein COVID-19 treatments with recommendations for potency assays to ensure consistent product quality.
Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance
The test was first granted the CE mark in October 2020 for use with nasopharyngeal swabs.
J&J Sees Delays in Coronavirus Vaccine Production as It Approaches Regulatory Finish Line
As Johnson & Johnson (J&J) nears the release of critical phase 3 trial results and potential emergency authorization for its promising COVID-19 vaccine, the company has reportedly hit speedbumps in manufacturing doses.
Operation Warp Speed Chief Adviser Moncef Slaoui Resigns
Operation Warp Speed (OWS)’s chief adviser Moncef Slaoui submitted his resignation Tuesday but said he will stay on in that role for 30 days after Jan. 21 to support the incoming administration.
Sinovac’s COVID-19 Vaccine Shows Only 50 Percent Efficacy in Brazil
Brazil’s Butantan Institute reported that Sinovac’s COVID-19 vaccine, CoronaVac, demonstrated an overall efficacy of only 50.38 percent in a phase 3 trial, putting it barely over the World Health Organization’s 50 percent efficacy threshold for approval.
COVID-19 Variants Raise Concern about Eli Lilly’s Antibody Treatment
Eli Lilly CEO David Ricks has expressed concern that the new variant of the coronavirus that causes COVID-19 first reported in South Africa might be resistant to the company’s antibody treatment bamlanivimab.
Biomerica Earns CE Mark for Rapid Coronavirus Test
The Irvine, Calif.-based company said it has already received orders for the test in Europe and is gearing up to ship them “in the coming weeks.”
AstraZeneca Seeks EU Approval of its COVID-19 Vaccine
AstraZeneca (AZ) has filed for EU approval of its COVID-19 vaccine and a conditional marketing authorization is expected in late January following a Jan. 29 meeting of the European Medicines Agency’s (EMA) expert panel on human medicines.
HHS Releases Withheld COVID-19 Doses, Changes State Allocation Policy
HHS announced yesterday it will no longer stockpile millions of COVID-19 vaccine doses held to ensure Americans receive their second shot, but will distribute them immediately and give states two weeks to comply with new federal rules for dose allocation.
Bharat Biotech to Supply its COVID-19 Vaccine to Brazil
Bharat Biotech has signed an agreement with the Brazilian company Precisa Medicamentos to supply 12 million doses of its India-developed COVID-19 vaccine Covaxin to Brazil.
Expert insights on clinical trials and COVID-19
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Submit a COVID-19 question or topic to be considered in future webinars
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.